Income Statement Presentation 2023
NME submissions and their additional indications
Projects in phase II and III
Roche
RG6026
RG6058
glofitamab + chemo
1L ctDNA+ high risk
DLBCL
tiragolumab +T
1L PD-L1+ cervical
RG6330
KRAS G12 C
2L NSCLC
zinpentraxin alfa
bepranemab
RG6416
Alzheimer's
RG6354
(PRM-151)
RG7314
balovaptan
post-traumatic stress
New Molecular Entity (NME)
Additional Indication (Al)
Oncology/Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
cancer
myelofibrosis
disorder
tiragolumab + T
RG6058 locally adv esophageal
Lunsumio (mosun) +
RG7828
lenalidomide
RG7816
Other
cancer
RG6058
tiragolumab + T
1L non-sq NSCLC
2L FL
Lunsumio (mosun) +
alogabat
(GABA Aa5 PAM)
ASD
RG7828
✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
PDS=Port Delivery System with ranibizumab
Mosun-mosunetuzumab
*First filed in China
Polivy
2L+ DLBCL (US)
RG7845
fenebrutinib
RMS
astegolimab
RG6058
tiragolumab + T
1L PD-L1+ MSCCHN
RG6149
(anti-ST2)
RG7845
fenebrutinib
PPMS
COPD
tiragolumab+T+/-
1IONIS managed
RG6058
chemo
NSCLC neoadj/adj
RG62991
ASO factor B
IgA nephropathy
RG7906
ralmitaront
schizophrenia
RG7854/
tiragolumab +T
RG6058
RG6107
1L PD-L1+ NSCLC
crovalimab
sickle cell disease
RG6346/
RG6084
ruzotolimod (TLR7 ago [3])/
xalnesiran (siRNA)/ PDL1 LNA
HBV
RG7935
prasinezumab
Parkinson's
tiragolumab + T
RG6058
1L esophageal cancer
RG6026
glofitamab+chemo
RG6139
2L DLBCL
PD1xLAG3
solid tumors
RG1662
(CN)
basmisanil
Dup 15q syndrome
RG6179
anti-IL-6
UME
RG6107
crovalimab⭑*
PNH (EU, US)
RG6058
tiragolumab + T
Stage III unresectable
giredestrant
tominersen
RG6171
(SERD)
RG6042
RG6179
Huntington's
anti-IL-6
DME
1L NSCLC
1L ER+/HER2-mBC
Susvimo
giredestrant
RG6321
(PDS)
DME (US)
RG6107
crovalimab
aHUS
RG6171
(SERD)
RG6100
semorinemab
Alzheimer's
RG62991
Susvimo
inavolisib
RG6026
glofitamab
3L+ DLBCL ✓
ER+ BC adj
giredestrant (SERD) +
RG6321
RG6107
crovalimab*
PNH (CN) ✓
RG7716
(PDS)
DR (US)
Vabysmo
(faricimab)
BRVO/CRVO
RG6114
(mPI3K alpha inh)
RG6171
Phesgo
RG6102
trontinemab
Alzheimer's
RG6321
ASO factor B
geographic atrophy
Susvimo
(PDS)
1L HR+ BC
1L ER+/HER2+ BC
WAMD, 36-week refill
delandistrogene
autogene cevumeran
RG6356
moxeparvovec
(SRP-9001) DMD (EU)
RG6180
RG6237
1L melanoma
latent myostatin +
Evrysdi
SMA
vicasinabin
RG7774 (CB2 receptor agonist)
DR
2022
2023
2024
2025 and beyond
Status as of February 2, 2023
79View entire presentation